Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.
Details
Serval ID
serval:BIB_6C66272E758C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.
Journal
Clinical physiology and functional imaging
ISSN
1475-097X (Electronic)
ISSN-L
1475-0961
Publication state
Published
Issued date
01/2018
Peer-reviewed
Oui
Volume
38
Number
1
Pages
4-9
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
The aim of this review was to summarize the recent developments on the role of positron emission tomography (PET) imaging using different radiopharmaceuticals in patients with multiple endocrine neoplasia (MEN) syndromes. Although most guidelines do not mention the use of PET imaging in patients with MEN syndromes, recent data seem to suggest a relevant diagnostic role of PET imaging in this setting. In particular, latest evidence has shown that somatostatin receptor PET provides a diagnostic accuracy in detecting MEN syndromes-related neuroendocrine tumours (NETs) higher than that of somatostatin receptor scintigraphy, thus influencing patient management in a significant percentage of cases. 18 F-DOPA PET seems to have a potential role in detecting MEN-2-related NETs, whereas 18 F-FDG PET is potentially useful in identifying aggressive NETs with poorer outcomes. More studies are needed to better define the role of different radiotracer-based PET imaging in patients with MEN syndromes.
Keywords
PET imaging, multiple endocrine neoplasia syndromes, neuroendocrine tumours
Pubmed
Create date
20/08/2017 17:34
Last modification date
20/08/2019 15:26